免疫治疗，尤其是抗PD-1和抗PD-L1抗体，可以明显改善晚期实体瘤患者的总体生存率，并克服不可避免的免疫相关不良事件（irAEs）。Camrelizumab是一种新型抗PD-1药物，报道最常见的irAEs是反应性毛细血管内皮增殖（RCCEP），尽管它广泛出现在皮肤上，但口腔RCCEP很少报道。一位59岁男子抱怨左下颌龈部有一个无痛结节已经两个多星期了。他两个月前由于食管鳞状细胞癌的复发开始注射卡瑞利珠单抗。在他的口腔粘膜上观察到一个8毫米的病变。然后，在他的皮肤上发现了几个弥漫的明亮的紫红色疙瘩。口腔病变和脸部的一个病变被手术切除。经过组织学检查确定为反应性毛细血管内皮增殖的最终诊断后，他的脸上其他可手术的病变被结扎切除。所有切除的病变在随访期内均有良好的预后，没有复发。随着卡瑞利珠单抗在其他实体肿瘤中的广泛使用，口腔RCCEP的发生率将增加。手术和结扎均是具有良好预后的RCCEP有效治疗方法。Copyright © 2023 Elsevier Ltd. All rights reserved.

Immunotherapy, especially anti-PD-1 and anti-PD-L1 antibodies, have observably improved the overall survival of patients with advanced solid tumors following the unavoidable immune-related adverse events (irAEs). Camrelizumab is a novel anti-PD-1 agent with the reported most common irAEs of reactive cutaneous capillary endothelial proliferation (RCCEP). Despite it is widely occurred in the skin, oral RCCEP is rarely reported.A 59-year-old man complained about a painless nodule on left mandibular gingiva for two weeks. He started to inject Camrelizumab because of the recurrence of esophageal squamous cell carcinoma two month ago. An 8 mm lesion was observed on his mucosa. Several disseminated bright purple red papules were then found on his skins. The oral lesion and one lesion on his face was removed by surgery. After the final diagnosis of reactive cutaneous capillary endothelial proliferation was confirmed by histological examination. Other operable lesions on his face were removed by ligation. All the removed lesions had a good prognosis without recurrence within the follow-up visit.With the widespread use of Camrelizumab in other solid tumors, the occurrence of oral RCCEP will increase. Surgery and ligation are both effective treatment for RCCEP with a good prognosis.Copyright © 2023 Elsevier Ltd. All rights reserved.